Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2020

01-12-2020 | Obesity | Research

Plasma biomarkers of small intestine adaptations in obesity-related metabolic alterations

Authors: Catherine Lalande, Jean-Philippe Drouin-Chartier, André J. Tremblay, Patrick Couture, Alain Veilleux

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Login to get access

Abstract

Background

Evidence suggests that pathophysiological conditions such as obesity and type 2 diabetes (T2D) are associated with morphologic and metabolic alterations in the small intestinal mucosa. Exploring these alterations generally requires invasive methods, limiting data acquisition to subjects with enteropathies or undergoing bariatric surgery. We aimed to evaluate small intestine epithelial cell homeostasis in a cohort of men covering a wide range of adiposity and glucose homoeostasis statuses.

Methods

Plasma levels of citrulline, a biomarker of enterocyte mass, and I-FABP, a biomarker of enterocyte death, were measured by UHPLC‑MS and ELISA in 154 nondiabetic men and 67 men with a T2D diagnosis.

Results

Plasma citrulline was significantly reduced in men with insulin resistance and T2D compared to insulin sensitive men. Decreased citrulline levels were, however, not observed in men with uncontrolled metabolic parameters during T2D. Plasma I-FABP was significantly higher in men with T2D, especially in presence of uncontrolled glycemic and lipid profile parameters. Integration of both parameters, which estimate enterocyte turnover, was associated with glucose homeostasis as well as with T2D diagnosis. Differences in biomarkers levels were independent of age and BMI and glucose filtration rates.

Conclusions

Our study supports a decreased functional enterocyte mass and an increased enterocyte death rate in presence of metabolic alterations but emphasizes that epithelial cell homeostasis is especially altered in presence of severe insulin resistance and T2D. The marked changes in small intestine cellularity observed in obesity and diabetes are thus suggested to be part of gut dysfunctions, mainly at an advanced stage of the disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dailey MJ. Nutrient-induced intestinal adaption and its effect in obesity. Physiol Behav. 2014;136:74–8.PubMedCrossRef Dailey MJ. Nutrient-induced intestinal adaption and its effect in obesity. Physiol Behav. 2014;136:74–8.PubMedCrossRef
2.
go back to reference Hutch CR, Sandoval DA. Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution? Ann N Y Acad Sci. 2017;1391:5–19.PubMedCrossRef Hutch CR, Sandoval DA. Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution? Ann N Y Acad Sci. 2017;1391:5–19.PubMedCrossRef
3.
go back to reference Shaw D, Gohil K, Basson MD. Intestinal mucosal atrophy and adaptation. World J Gastroenterol WJG. 2012;18:6357–75.PubMedCrossRef Shaw D, Gohil K, Basson MD. Intestinal mucosal atrophy and adaptation. World J Gastroenterol WJG. 2012;18:6357–75.PubMedCrossRef
4.
go back to reference Verdam FJ, Greve JWM, Roosta S, van Eijk H, Bouvy N, Buurman WA, et al. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2010;96:E379–83.PubMedCrossRef Verdam FJ, Greve JWM, Roosta S, van Eijk H, Bouvy N, Buurman WA, et al. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2010;96:E379–83.PubMedCrossRef
5.
go back to reference Monteiro-Sepulveda M, Touch S, Mendes-Sá C, André S, Poitou C, Allatif O, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab. 2015;22:113–24.PubMedCrossRef Monteiro-Sepulveda M, Touch S, Mendes-Sá C, André S, Poitou C, Allatif O, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab. 2015;22:113–24.PubMedCrossRef
6.
go back to reference Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518.PubMedCrossRef Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518.PubMedCrossRef
7.
go back to reference Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.PubMedCrossRef Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.PubMedCrossRef
8.
go back to reference Veilleux A, Mayeur S, Bérubé J-C, Beaulieu J-F, Tremblay E, Hould F-S, et al. Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis. BMC Gastroenterol. 2015;15:119.PubMedPubMedCentralCrossRef Veilleux A, Mayeur S, Bérubé J-C, Beaulieu J-F, Tremblay E, Hould F-S, et al. Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis. BMC Gastroenterol. 2015;15:119.PubMedPubMedCentralCrossRef
9.
go back to reference Tomlinson C, Rafii M, Ball RO, Pencharz PB. Arginine can be synthesized from enteral proline in healthy adult humans. J Nutr. 2011;141:1432–6.PubMedCrossRef Tomlinson C, Rafii M, Ball RO, Pencharz PB. Arginine can be synthesized from enteral proline in healthy adult humans. J Nutr. 2011;141:1432–6.PubMedCrossRef
10.
go back to reference Marini JC, Agarwal U, Didelija IC, Azamian M, Stoll B, Nagamani SC. Plasma glutamine is a minor precursor for the synthesis of citrulline: a multispecies study. J Nutr. 2017;147:549–55.PubMedPubMedCentralCrossRef Marini JC, Agarwal U, Didelija IC, Azamian M, Stoll B, Nagamani SC. Plasma glutamine is a minor precursor for the synthesis of citrulline: a multispecies study. J Nutr. 2017;147:549–55.PubMedPubMedCentralCrossRef
12.
go back to reference Neis EPJG, Sabrkhany S, Hundscheid I, Schellekens D, Lenaerts K, Olde Damink SW, et al. Human splanchnic amino-acid metabolism. Amino Acids. 2017;49:161–72.PubMedCrossRef Neis EPJG, Sabrkhany S, Hundscheid I, Schellekens D, Lenaerts K, Olde Damink SW, et al. Human splanchnic amino-acid metabolism. Amino Acids. 2017;49:161–72.PubMedCrossRef
13.
go back to reference Breuillard C, Cynober L, Moinard C. Citrulline and nitrogen homeostasis: an overview. Amino Acids. 2015;47:685–91.PubMedCrossRef Breuillard C, Cynober L, Moinard C. Citrulline and nitrogen homeostasis: an overview. Amino Acids. 2015;47:685–91.PubMedCrossRef
14.
go back to reference Hoffmanová I, Sánchez D, Hábová V, Anděl M, Tučková L, Tlaskalová-Hogenová H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2. Physiol Res. 2015;64:537–46.PubMed Hoffmanová I, Sánchez D, Hábová V, Anděl M, Tučková L, Tlaskalová-Hogenová H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2. Physiol Res. 2015;64:537–46.PubMed
15.
go back to reference Papadia C, Sherwood RA, Kalantzis C, Wallis K, Volta U, Fiorini E, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102:1474–82.PubMedCrossRef Papadia C, Sherwood RA, Kalantzis C, Wallis K, Volta U, Fiorini E, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102:1474–82.PubMedCrossRef
16.
go back to reference Shen L-J, Guan Y-Y, Wu X-P, Wang Q, Wang L, Xiao T, et al. Serum citrulline as a diagnostic marker of sepsis-induced intestinal dysfunction. Clin Res Hepatol Gastroenterol. 2015;39:230–6.PubMedCrossRef Shen L-J, Guan Y-Y, Wu X-P, Wang Q, Wang L, Xiao T, et al. Serum citrulline as a diagnostic marker of sepsis-induced intestinal dysfunction. Clin Res Hepatol Gastroenterol. 2015;39:230–6.PubMedCrossRef
17.
go back to reference David AI, Selvaggi G, Ruiz P, Gaynor JJ, Tryphonopoulos P, Kleiner GI, et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation. 2007;84:1077–81.PubMedCrossRef David AI, Selvaggi G, Ruiz P, Gaynor JJ, Tryphonopoulos P, Kleiner GI, et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation. 2007;84:1077–81.PubMedCrossRef
18.
go back to reference Lutgens L, Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma citrulline. World J Gastroenterol. 2007;13:3033–42.PubMedPubMedCentralCrossRef Lutgens L, Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma citrulline. World J Gastroenterol. 2007;13:3033–42.PubMedPubMedCentralCrossRef
19.
go back to reference Crenn P, Truchis PD, Neveux N, Galpérine T, Cynober L, Melchior JC. Plasma citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients. Am J Clin Nutr. 2009;90:587–94.PubMedCrossRef Crenn P, Truchis PD, Neveux N, Galpérine T, Cynober L, Melchior JC. Plasma citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients. Am J Clin Nutr. 2009;90:587–94.PubMedCrossRef
20.
go back to reference Voth M, Holzberger S, Auner B, Henrich D, Marzi I, Relja B. I-FABP and L-FABP are early markers for abdominal injury with limited prognostic value for secondary organ failures in the post-traumatic course. Clin Chem Lab Med CCLM FESCC. 2015;53:771–80. Voth M, Holzberger S, Auner B, Henrich D, Marzi I, Relja B. I-FABP and L-FABP are early markers for abdominal injury with limited prognostic value for secondary organ failures in the post-traumatic course. Clin Chem Lab Med CCLM FESCC. 2015;53:771–80.
21.
go back to reference Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011;46:1435–41.PubMedCrossRef Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011;46:1435–41.PubMedCrossRef
22.
go back to reference Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery. 1997;121:335–42.PubMedCrossRef Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery. 1997;121:335–42.PubMedCrossRef
23.
go back to reference Tremblay AJ, Lamarche B, Guay V, Charest A, Lemelin V, Couture P. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr. 2013;98:32–41.PubMedCrossRef Tremblay AJ, Lamarche B, Guay V, Charest A, Lemelin V, Couture P. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr. 2013;98:32–41.PubMedCrossRef
24.
go back to reference Tremblay AJ, Lamarche B, Labonte M-E, Lepine M-C, Lemelin V, Couture P. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Am J Clin Nutr. 2014;99:54–61.PubMedCrossRef Tremblay AJ, Lamarche B, Labonte M-E, Lepine M-C, Lemelin V, Couture P. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Am J Clin Nutr. 2014;99:54–61.PubMedCrossRef
25.
go back to reference Couture P, Tremblay AJ, Kelly I, Lemelin V, Droit A, Lamarche B. Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. J Lipid Res. 2014;55:128–37.PubMedPubMedCentralCrossRef Couture P, Tremblay AJ, Kelly I, Lemelin V, Droit A, Lamarche B. Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. J Lipid Res. 2014;55:128–37.PubMedPubMedCentralCrossRef
26.
go back to reference Tremblay AJ, Lamarche B, Kelly I, Charest A, Lépine M-C, Droit A, et al. Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:1223–9.PubMedCrossRef Tremblay AJ, Lamarche B, Kelly I, Charest A, Lépine M-C, Droit A, et al. Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:1223–9.PubMedCrossRef
27.
go back to reference Hogue J-C, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57:246–54.PubMedCrossRef Hogue J-C, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57:246–54.PubMedCrossRef
28.
go back to reference Hogue J-C, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism. 2008;57:380–6.PubMedCrossRef Hogue J-C, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism. 2008;57:380–6.PubMedCrossRef
29.
go back to reference Tremblay AJ, Lamarche B, Lemelin V, Hoos L, Benjannet S, Seidah NG, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res. 2011;52:558–65.PubMedPubMedCentralCrossRef Tremblay AJ, Lamarche B, Lemelin V, Hoos L, Benjannet S, Seidah NG, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res. 2011;52:558–65.PubMedPubMedCentralCrossRef
30.
go back to reference Tremblay AJ. Effect of ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:1101–6.PubMedCrossRef Tremblay AJ. Effect of ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:1101–6.PubMedCrossRef
31.
go back to reference Tremblay AJ, Lamarche B, Hogue J-C, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res. 2009;50:1463–71.PubMedPubMedCentralCrossRef Tremblay AJ, Lamarche B, Hogue J-C, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res. 2009;50:1463–71.PubMedPubMedCentralCrossRef
32.
go back to reference Drouin-Chartier J-P, Tremblay AJ, Lemelin V, Lépine M-C, Lamarche B, Couture P. Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance. Diabetes Obes Metab. 2016;18:1226–35.PubMedCrossRef Drouin-Chartier J-P, Tremblay AJ, Lemelin V, Lépine M-C, Lamarche B, Couture P. Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance. Diabetes Obes Metab. 2016;18:1226–35.PubMedCrossRef
33.
go back to reference Drouin-Chartier J-P, Gigleux I, Tremblay AJ, Poirier L, Lamarche B, Couture P. Impact of dairy consumption on essential hypertension: a clinical study. Nutr J. 2014;13:83.PubMedPubMedCentralCrossRef Drouin-Chartier J-P, Gigleux I, Tremblay AJ, Poirier L, Lamarche B, Couture P. Impact of dairy consumption on essential hypertension: a clinical study. Nutr J. 2014;13:83.PubMedPubMedCentralCrossRef
34.
go back to reference Tremblay AJ, Lamarche B, Ruel IL, Hogue J-C, Bergeron J, Gagné C, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res. 2004;45:866–72.PubMedCrossRef Tremblay AJ, Lamarche B, Ruel IL, Hogue J-C, Bergeron J, Gagné C, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res. 2004;45:866–72.PubMedCrossRef
35.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
36.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef
37.
go back to reference Drouin-Chartier J-P, Tremblay AJ, Lemelin V, Lamarche B, Couture P. Differential associations between plasma concentrations of insulin and glucose and intestinal expression of key genes involved in chylomicron metabolism. Am J Physiol-Gastrointest Liver Physiol. 2018;315:G177–84.PubMedCrossRef Drouin-Chartier J-P, Tremblay AJ, Lemelin V, Lamarche B, Couture P. Differential associations between plasma concentrations of insulin and glucose and intestinal expression of key genes involved in chylomicron metabolism. Am J Physiol-Gastrointest Liver Physiol. 2018;315:G177–84.PubMedCrossRef
38.
go back to reference Moon J, Kim OY, Jo G, Shin M-J. Alterations in circulating amino acid metabolite ratio associated with arginase activity are potential indicators of metabolic syndrome: The Korean Genome and Epidemiology Study. Nutrients. 2017;9:740.PubMedCentralCrossRef Moon J, Kim OY, Jo G, Shin M-J. Alterations in circulating amino acid metabolite ratio associated with arginase activity are potential indicators of metabolic syndrome: The Korean Genome and Epidemiology Study. Nutrients. 2017;9:740.PubMedCentralCrossRef
39.
go back to reference Levy E, Spahis S, Ziv E, Marette A, Elchebly M, Lambert M, et al. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia. 2006;49:1937–45.PubMedCrossRef Levy E, Spahis S, Ziv E, Marette A, Elchebly M, Lambert M, et al. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia. 2006;49:1937–45.PubMedCrossRef
40.
go back to reference Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes. 2006;55:1316–26.PubMedCrossRef Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes. 2006;55:1316–26.PubMedCrossRef
41.
go back to reference Haidari M. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. J Biol Chem. 2002;277:31646–55.PubMedCrossRef Haidari M. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. J Biol Chem. 2002;277:31646–55.PubMedCrossRef
42.
go back to reference Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146:247–55.PubMedCrossRef Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146:247–55.PubMedCrossRef
43.
go back to reference Ramírez-Zamora S, Méndez-Rodríguez ML, Olguín-Martínez M, Sánchez-Sevilla L, Quintana-Quintana M, García-García N, et al. Increased erythrocytes by-products of arginine catabolism are associated with hyperglycemia and could be involved in the pathogenesis of type 2 diabetes mellitus. PLoS ONE. 2013;8:e66823.PubMedPubMedCentralCrossRef Ramírez-Zamora S, Méndez-Rodríguez ML, Olguín-Martínez M, Sánchez-Sevilla L, Quintana-Quintana M, García-García N, et al. Increased erythrocytes by-products of arginine catabolism are associated with hyperglycemia and could be involved in the pathogenesis of type 2 diabetes mellitus. PLoS ONE. 2013;8:e66823.PubMedPubMedCentralCrossRef
44.
go back to reference Adam J, Brandmaier S, Leonhardt J, Scheerer MF, Mohney RP, Xu T, et al. Metformin effect on nontargeted metabolite profiles in patients with type 2 diabetes and in multiple murine tissues. Diabetes. 2016;65:3776–85.PubMedCrossRef Adam J, Brandmaier S, Leonhardt J, Scheerer MF, Mohney RP, Xu T, et al. Metformin effect on nontargeted metabolite profiles in patients with type 2 diabetes and in multiple murine tissues. Diabetes. 2016;65:3776–85.PubMedCrossRef
46.
go back to reference Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, et al. Effect of insulin sensitizer therapy on amino acids and their metabolites. Metabolism. 2015;64:720–8.PubMedPubMedCentralCrossRef Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, et al. Effect of insulin sensitizer therapy on amino acids and their metabolites. Metabolism. 2015;64:720–8.PubMedPubMedCentralCrossRef
47.
go back to reference Piton G, Manzon C, Cypriani B, Carbonnel F, Capellier G. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker? Intensive Care Med. 2011;37:911–7.PubMedCrossRef Piton G, Manzon C, Cypriani B, Carbonnel F, Capellier G. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker? Intensive Care Med. 2011;37:911–7.PubMedCrossRef
48.
go back to reference van de Poll MCG, Ligthart-Melis GC, Boelens PG, Deutz NEP, van Leeuwen PAM, Dejong CHC. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol. 2007;581:819–27.PubMedPubMedCentralCrossRef van de Poll MCG, Ligthart-Melis GC, Boelens PG, Deutz NEP, van Leeuwen PAM, Dejong CHC. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol. 2007;581:819–27.PubMedPubMedCentralCrossRef
Metadata
Title
Plasma biomarkers of small intestine adaptations in obesity-related metabolic alterations
Authors
Catherine Lalande
Jean-Philippe Drouin-Chartier
André J. Tremblay
Patrick Couture
Alain Veilleux
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00530-6

Other articles of this Issue 1/2020

Diabetology & Metabolic Syndrome 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine